PortfoliosLab logoPortfoliosLab logo
GLP Weigh Loss
Performance
Return for Risk
Dividends
Drawdowns
Volatility
Diversification

Asset Allocation


S&P 500 Index

Portfolio Optimizer

Find the right asset allocation for GLP Weigh Loss

Add portfolio to the optimizer to find optimal allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in GLP Weigh Loss , comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends. The portfolio is rebalanced Every 3 months.


Loading charts...

Returns By Period


Position1D1MYTD6M1Y3Y*5Y*10Y*
Benchmark
S&P 500 Index
0.30%0.09%8.18%8.17%23.42%19.88%11.91%13.45%
Portfolio
GLP Weigh Loss
-1.65%-0.72%-5.05%-1.48%18.39%24.73%27.18%
ALNY
Alnylam Pharmaceuticals, Inc.
-3.59%-0.98%-26.53%-32.06%-2.88%15.25%13.17%16.55%
AMGN
Amgen Inc.
-1.10%5.02%7.16%9.19%22.66%20.11%11.06%11.65%
AZN
AstraZeneca PLC
-2.37%-0.71%0.81%1.53%28.04%9.54%12.08%15.85%
HIMS
Hims & Hers Health, Inc.
3.74%-3.89%-16.32%-30.55%-51.77%44.53%15.10%
LLY
Eli Lilly and Company
1.57%21.37%7.29%15.58%50.32%38.07%39.75%33.71%
MCK
McKesson Corporation
-1.16%4.27%-6.36%-3.74%7.98%25.42%32.82%16.13%
NVO
Novo Nordisk A/S
-4.52%-10.96%-16.56%-9.23%-42.47%-17.53%1.78%6.20%
REGN
Regeneron Pharmaceuticals, Inc.
-3.79%-14.36%-20.58%-12.84%24.63%-6.19%3.39%5.18%
TEVA
Teva Pharmaceutical Industries Limited
-2.72%-6.91%6.57%17.40%87.17%65.55%25.39%-4.15%
VKTX
Viking Therapeutics, Inc.
2.78%-6.67%-16.88%-23.01%5.07%6.41%39.22%36.31%
*Multi-year figures are annualized to reflect compound growth (CAGR)

Monthly Returns

Based on dividend-adjusted daily data since Sep 16, 2019, GLP Weigh Loss 's average daily return is +0.11%, while the average monthly return is +2.22%. At this rate, an investment would double in approximately 2.6 years.

Historically, 62% of months were positive and 38% were negative. The best month was Feb 2024 with a return of +20.2%, while the worst month was Oct 2020 at -8.5%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 4 months.

On a daily basis, GLP Weigh Loss closed higher 53% of trading days. The best single day was Feb 27, 2024 with a return of +14.1%, while the worst single day was Mar 12, 2020 at -9.3%.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
20260.41%-0.24%-6.22%1.50%2.14%-2.52%-5.05%
20251.19%4.57%-6.74%0.71%-0.64%0.58%-1.15%5.14%1.57%7.03%12.86%-0.71%25.76%
20248.35%20.24%4.85%-0.64%6.26%8.53%0.09%7.58%-6.87%-3.80%-4.93%-5.31%35.94%
20230.05%-2.43%9.45%5.34%-2.57%0.64%0.67%9.16%-1.39%-4.02%8.22%7.72%33.81%
2022-6.24%2.73%9.11%-4.44%2.33%-0.12%4.10%1.65%-3.40%13.39%5.48%11.91%40.43%
202110.80%-4.11%0.76%0.47%2.64%7.45%2.93%5.27%-4.79%1.61%-2.19%4.25%26.80%

Benchmark Metrics

GLP Weigh Loss has an annualized alpha of 18.40%, beta of 0.70, and R2 of 0.38 versus S&P 500 Index. Calculated based on daily prices since September 16, 2019.

  • This portfolio participates in less of S&P 500 Index's moves in both directions, but captures a larger share of gains (93.63%) than losses (30.62%) - typical of diversified or defensive assets.
  • Beta of 0.70 may look defensive, but with R2 of 0.38 this portfolio is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this portfolio's risk.
  • R2 of 0.38 means the benchmark explains less than half of this portfolio's behavior - treat beta with caution or consider switching to a more representative benchmark.

Alpha
18.40%
Beta
0.70
0.38
Upside Capture
93.63%
Downside Capture
30.62%

Expense Ratio

GLP Weigh Loss has an expense ratio of 0.00%, meaning no management fees are charged. Below, you can find the expense ratios of the portfolio's funds side by side and easily compare their relative costs.


The portfolio doesn't include any funds that charge management fees.

Return for Risk

Risk / Return Rank

GLP Weigh Loss ranks 12 for risk / return — in the bottom 12% of Portfolios on our site. This means you're taking on significantly more risk than the returns justify. Consider whether the potential upside is worth the volatility, or explore alternatives with better risk / return profiles.


GLP Weigh Loss Risk / Return Rank: 1212
Overall Rank
GLP Weigh Loss Sharpe Ratio Rank: 1111
Sharpe Ratio Rank
GLP Weigh Loss Sortino Ratio Rank: 1212
Sortino Ratio Rank
GLP Weigh Loss Omega Ratio Rank: 1111
Omega Ratio Rank
GLP Weigh Loss Calmar Ratio Rank: 1515
Calmar Ratio Rank
GLP Weigh Loss Martin Ratio Rank: 1212
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

Return / Risk — by metrics

The table below presents risk-adjusted performance metrics for GLP Weigh Loss and compares them with S&P 500 Index.


PortfolioBenchmarkDifference
Sharpe ratioReturn per unit of total volatility

0.88

1.94

-1.05

Sortino ratioReturn per unit of downside risk

1.38

2.63

-1.24

Omega ratioGain probability vs. loss probability

1.16

1.35

-0.19

Calmar ratioReturn relative to maximum drawdown

1.41

2.59

-1.17

Martin ratioReturn relative to average drawdown

3.48

11.84

-8.37


How much return does each position deliver for the risk it carries? Higher values mean better reward for the risk taken.

PositionRisk / Return RankSharpe ratioSortino ratioOmega ratioCalmar ratioMartin ratio
ALNY
Alnylam Pharmaceuticals, Inc.
38-0.080.151.02-0.07-0.12
AMGN
Amgen Inc.
660.831.401.171.373.21
AZN
AstraZeneca PLC
731.111.831.211.834.90
HIMS
Hims & Hers Health, Inc.
20-0.54-0.420.95-0.67-1.09
LLY
Eli Lilly and Company
771.331.901.262.145.32
MCK
McKesson Corporation
490.280.651.080.290.79
NVO
Novo Nordisk A/S
12-0.82-1.010.86-0.77-1.14
REGN
Regeneron Pharmaceuticals, Inc.
640.751.261.160.963.20
TEVA
Teva Pharmaceutical Industries Limited
902.253.421.434.0210.94
VKTX
Viking Therapeutics, Inc.
460.070.631.100.110.23

Sharpe Ratio

The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.

GLP Weigh Loss Sharpe ratios as of Jun 9, 2026 (values are recalculated daily):

  • 1-Year: 0.88
  • 5-Year: 1.28
  • All Time: 1.25

These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns (including price changes and dividends).

Compared to the broad market, where average Sharpe ratios range from 1.62 to 2.52, this portfolio's current Sharpe ratio places it in the bottom 25%. This suggests weaker risk-adjusted returns than most portfolios, possibly due to lower returns, higher volatility, or both. It may be worth reviewing the allocation. You can use the Portfolio Optimization tool to explore options for improving the Sharpe ratio.

The chart below shows the rolling Sharpe ratio of GLP Weigh Loss compared to the selected benchmark. This view highlights how the investment's risk-adjusted performance has changed over time.


Loading charts...

Dividends

Dividend yield

GLP Weigh Loss provided a 1.53% dividend yield over the last twelve months.


PositionTTM20252024202320222021202020192018201720162015
Portfolio1.53%1.22%1.09%0.93%1.00%1.11%1.29%1.33%1.37%1.83%2.14%1.41%
ALNY
Alnylam Pharmaceuticals, Inc.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
AMGN
Amgen Inc.
2.83%2.91%3.45%2.96%2.95%3.13%2.78%2.41%2.71%2.65%2.74%1.95%
AZN
AstraZeneca PLC
2.93%1.70%2.27%2.15%2.12%2.35%2.80%2.81%3.69%3.95%5.01%4.06%
HIMS
Hims & Hers Health, Inc.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
LLY
Eli Lilly and Company
0.56%0.56%0.67%0.78%1.07%1.23%1.75%1.96%1.94%2.46%2.77%2.37%
MCK
McKesson Corporation
0.43%0.37%0.47%0.50%0.54%0.72%0.95%1.16%1.32%0.80%0.80%0.53%
NVO
Novo Nordisk A/S
4.39%3.31%1.68%1.00%1.20%1.35%1.87%2.14%1.45%1.52%2.87%0.92%
REGN
Regeneron Pharmaceuticals, Inc.
0.60%0.46%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
TEVA
Teva Pharmaceutical Industries Limited
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%3.88%3.19%1.77%
VKTX
Viking Therapeutics, Inc.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading charts...

Worst Drawdowns

The table below displays the maximum drawdowns of the GLP Weigh Loss . A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the GLP Weigh Loss was 29.72%, occurring on Apr 8, 2025. Recovery took 160 trading sessions.

The current GLP Weigh Loss drawdown is 8.87%.


Related event

Drawdown

Fall

Recovery

Underwater

2025 selloff2025
-29.72%Apr 2025
7mo 7d7mo 21d
1y 2moSep 2024 - Nov 2025
COVID crash2020
-21.83%Mar 2020
1mo 9d25d
2mo 4dFeb 2020 - Apr 2020
2020 correction2020
-16.67%Oct 2020
3mo 11d2mo 17d
5mo 28dJul 2020 - Jan 2021
Bear market2022
-14.94%Jun 2022
2mo 6d1mo 19d
3mo 25dApr 2022 - Aug 2022
Bear market2022
-13.76%Sep 2022
1mo 11d1mo 2d
2mo 13dAug 2022 - Oct 2022

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading charts...

Diversification

Diversification Metrics


Number of Effective Assets

The portfolio contains 10 assets, with an effective number of assets of 8.67, reflecting the diversification based on asset allocation. Your capital is well-distributed across most of your holdings, with only mild concentration in a few names. True diversification also depends on the correlations between assets — check the diversification ratio below.


Diversification Ratio
1Y
3Y
5Y
All Time
Diversification Ratio

1.89

1.88

1.89

1.77

The portfolio has a diversification ratio of 1.77, in line with the typical range across portfolios. There's room to improve by adding less correlated assets.

GLP Weigh Loss correlation to the S&P 500 Index

GLP Weigh Loss has a 0.45 correlation to S&P 500 Index over the trailing 12 months. This section compares each holding's correlation to the benchmark and to the portfolio.

Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.45

Correlation (3Y)
Calculated over the trailing 3-year period

0.46

Correlation (5Y)
Calculated over the trailing 5-year period

0.52

Correlation (All Time)
Calculated using the full available price history since Sep 16, 2019

0.54


Benchmark Correlations

Correlation vs. S&P 500 Index. TEVA has the highest benchmark correlation at 0.40, while AZN has the lowest at 0.29.

AZN
0.29
MCK
0.31
ALNY
0.34
LLY
0.34
REGN
0.36
NVO
0.36
VKTX
0.36
HIMS
0.37
AMGN
0.39
TEVA
0.40

Portfolio Correlations

Correlation vs. GLP Weigh Loss . LLY has the highest portfolio correlation at 0.64, while HIMS has the lowest at 0.30.

HIMS
0.30
MCK
0.40
TEVA
0.53
ALNY
0.55
AZN
0.55
NVO
0.60
REGN
0.60
VKTX
0.61
AMGN
0.61
LLY
0.64

Asset Correlations Table

The table below displays the correlation coefficients between the individual components of the portfolio, the entire portfolio, and the chosen benchmark.

The correlation results are calculated based on daily price changes starting from Sep 16, 2019
Diversification Analysis

Find what GLP Weigh Loss is missing

See which holdings overlap, where GLP Weigh Loss is concentrated, and which low-correlation assets could fill the gaps.

Analyze Diversification